Drug Specific: sofpironium bromide (Sofdra)
Customize your policy alerts
Sign up for allcareadvantage Policy UMCCOMED129.1 alerts
Get alerted when Policy UMCCOMED129.1 changes without checking for updates manually.
Monitor payer policy activity
Defines AllCare Advantage coverage and prior authorization criteria for sofpironium bromide (Sofdra) for members with primary axillary hyperhidrosis, including initial and renewal requirements, approval lengths, and quantity limits.
No material clinical or coverage changes in this revision.
Coverage Criteria for Sofpironium bromide (Sofdra)
inv-01: Initial Therapy
Covered when ALL of the following are met:
Initial approval up to 6 months; quantity limit 1.34 mL/day.
inv-02: Continuation Therapy
Renewal covered when ALL of the following are met:
Renewal approvals up to 12 months.
The policy excludes pediatric patients younger than 9 years because the safety and effectiveness have not been established for that age group. Requests for members under 9 years should be processed as not meeting the coverage criteria and forwarded for medical director review per the policy.
Requests that do not meet the policy’s required age, diagnostic, objective severity, prior therapy, or quantity limit criteria are processed as not meeting criteria and forwarded to a medical director for review. In practice this means nonconforming uses (for example, missing GSP or HDSM-Ax7 documentation, no documented trial of required topical therapies, or exceeding the quantity limit) will be handled as not meeting criteria rather than approved.
Initial Authorization Criteria
inv-14: Initial Therapy
Initial authorization criteria and limits
Approval length up to 6 months; quantity limit 1.34 mL/day.
Renewal / Continuation Requirements
inv-15: Renewal
Renewal requirements
Renewal approval up to 12 months.
Provider Actions and Administrative Requirements
Prior authorization required; initial up to 6 months, renewals up to 12 months
Prior authorization is required for sofpironium bromide (Sofdra). Initial approvals are granted for up to 6 months; renewal approvals may be granted for up to 12 months.
Step therapy: trial of aluminum chloride and preferred topical anticholinergic expected
Before sofpironium is approved, the member must have documented trials of a prescription‑strength aluminum chloride product and a preferred topical anticholinergic (for example, glycopyrronium tosylate/Qbrexza); documentation of the trial of the preferred topical anticholinergic is required.
Required documentation to support diagnosis, duration, and objective severity
Submit documentation that supports a diagnosis of primary axillary hyperhidrosis: focal, visible, excessive underarm sweating for at least 6 months with secondary causes ruled out, and objective severity data as either GSP >50 mg per axilla (combined ≥150 mg/5 minutes) or HDSM‑Ax7 score ≥3.
- Evidence of focal, visible, excessive sweating ≥6 months and exclusion of secondary causes
- Gravimetric sweat production (GSP) measurements or HDSM‑Ax7 score documented per criteria
Denial triggers: non‑adherence to age, diagnostic, severity, prior therapy, or quantity criteria
Requests that fail to meet the policy age, diagnostic, severity, prior‑therapy, or quantity‑limit criteria are forwarded to a medical director for review and may be denied.
- Patients younger than 9 years: safety and effectiveness not established; do not meet criteria
- Missing required trials of aluminum chloride or preferred topical anticholinergic
- Objective severity not documented (GSP or HDSM‑Ax7) or quantity limit exceeded (1.34 mL/day)
Step Therapy Requirements
| Step | Requirement | Notes |
|---|---|---|
| Step 1 | ||
| Trial of prescription-strength aluminum chloride (e.g., Drysol) | ||
| First-line agent required before advancing to Step 2; document trial | ||
| Step 2 | ||
| Trial of a preferred topical anticholinergic (e.g., glycopyrronium tosylate [Qbrexza]) | ||
| Documentation of trial of preferred topical anticholinergic is required prior to approval of sofpironium; must confirm sofpironium will not be used concurrently with other topical anticholinergics |
Severity Thresholds and Measurement
Definitions
Background
Primary axillary hyperhidrosis is a focal disorder characterized by visible, excessive underarm sweating. First-line management typically includes topical antiperspirants such as prescription-strength aluminum chloride and topical anticholinergics; more invasive treatments (for example, botulinum toxin) are considered second- or third-line. Sofpironium bromide (Sofdra) is an approved topical anticholinergic alternative for treatment of primary axillary hyperhidrosis and is covered by this policy when the specified clinical and objective severity criteria are met.
Quantity Limits
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.